Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6


Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.

Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Doria-Rose VP, Laiyemo AO, Church T, Yokochi LA, Yurgalevitch S, Rathmell J, Andriole GL, Buys S, Crawford ED, Fouad M, Isaacs C, Lamerato L, Reding D, Prorok PC, Berg CD; PLCO Project Team.

J Natl Cancer Inst. 2012 Feb 22;104(4):280-9. doi: 10.1093/jnci/djr549. Epub 2012 Jan 31.


Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.

Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.


Cumulative incidence of false-positive results in repeated, multimodal cancer screening.

Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE.

Ann Fam Med. 2009 May-Jun;7(3):212-22. doi: 10.1370/afm.942.


Sexually transmissible infections and prostate cancer risk.

Huang WY, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF, Reding D, Whitby D, Papp JR, Rabkin CS.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2374-81. doi: 10.1158/1055-9965.EPI-08-0173.


Overdiagnosis and overtreatment of early detected prostate cancer.

Bangma CH, Roemeling S, Schröder FH.

World J Urol. 2007 Mar;25(1):3-9. Epub 2007 Feb 14. Review.

Supplemental Content

Support Center